Nurtec new acute migraine treatment 2025?

Short answer: As of my latest general knowledge, there hasn’t been a widely publicized new acute-migraine indication for Nurtec (rimegepant) in 2025. Nurtec remains approved for acute treatment of migraine in adults and for preventive treatment of episodic migraine in adults. If there have been any new regulatory changes or label updates in 2025, they would be announced by the FDA and the product sponsor (Pfizer/Biohaven).

If you want to verify the very latest status, I can help you check:
- FDA Drugs@FDA label for Nurtec (rimegepant)
- DailyMed entry for rimegepant
- Pfizer/Biohaven press releases or investor updates
- ClinicalTrials.gov for any ongoing or recently completed trials

Would you like me to guide you to these sources or summarize any specific update you’ve seen? I can also explain how Nurtec is used (acute vs preventive) and how that might fit into your migraine treatment plan.